Back to Search
Start Over
Which treatment to prevent an imminent fracture?
- Source :
- Bone Reports, Vol 15, Iss, Pp 101105-(2021), Bone Reports
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Purpose To provide a summarized state of the art of the relative efficacy and rapidity of action of pharmacological treatments to prevent imminent osteoporotic fractures. Methods We reviewed metanalyses (MA) and network metaanalyses (NMA) published during the last 10 years concerning the pharmacological treatment of osteoporosis. We compared the anti-fracture efficacy and the rapidity of action of various agents versus placebo and versus risedronate. Results All bisphosphonates decrease the incidence of vertebral fractures compared with placebo. Ibandronate is the only one without demonstrated efficacy against non-vertebral and hip fractures. Zoledronate, denosumab and anabolic therapy are associated with a higher fracture risk reduction than oral bisphosphonates. Compared with risedronate, which significantly reduces the rate of hip fractures, zoledronate, denosumab, teriparatide, abaloparatide and romosozumab are more efficient for vertebral fractures but not for non-vertebral or hip fractures reduction. No studies have compared bone anabolic treatments with zoledronate or denosumab. Oral bisphosphonates significantly reduce fracture risk only after more than one year of therapy. A faster reduction of fracture risk is observed with zoledronate and denosumab, or with anabolic agents. For denosumab and anabolic agents, a sequential treatment is required to keep gains after treatment withdrawal. Conclusions In patients at high risk of imminent fracture, starting therapy with potent antiresorptive agents or with an anabolic agent seems most appropriate to promptly reduce the fracture risk. Available NMA/MA suggest that, compared to zoledronate and denosumab, anabolic agents have a higher efficacy for vertebral fractures but head-to-head studies are lacking.<br />Highlights • The concept of imminent fracture has implications for the choice of therapy • We reviewed metanalyses and network metaanalyses published in the last 10 years • We compared the efficacy and rapidity of treatments to prevent imminent fractures • Potent antiresorptive and anabolic agents are most appropriate to promptly reduce fracture risk • Anabolic agents seem to be more efficient to reduce vertebral fracture risk
- Subjects :
- medicine.medical_specialty
Anabolic
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Abaloparatide
Osteoporosis
Romosozumab
Urology
Diseases of the musculoskeletal system
Placebo
Anabolic Agents
Imminent fracture
medicine
Teriparatide
Bisphosphonate
Orthopedics and Sports Medicine
business.industry
Mini-Review
medicine.disease
Denosumab
RC925-935
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 23521872
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Bone Reports
- Accession number :
- edsair.doi.dedup.....f85dbe35b7a00e79868fd0c26e42c3e6